A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene

Stopped early · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica, Dominant

In brief

A double-blind, randomized, intra-subject placebo-controlled, multicenter, multiple dose study, evaluating safety, proof of mechanism, preliminary efficacy and systemic exposure in subjects with confirmed DDEB or RDEB diagnosis with one or more pathogenic mutations in exon 73 in the COL7A1 gene.

Key facts

Study ID

NCT03605069

Run by

Phoenicis Therapeutics

People needed

2

Starts

2018-07-02

Expected to finish

2018-12-17

Last updated by the study team

2021-08-25

Who can join

Age: 4 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female, ≥ 4 years of age at Screening with a clinical diagnosis of DDEB or RDEB and at least one pathogenic mutation in exon 73 of the COL7A1 gene.
• Have at least one TWA, ie, a skin area of 7 x 7 cm that ishows no signs of local infection, and contains a target wound that is either new or shows dynamic wound healing and complies to the following additional criteria:
• surface area of the target wound ranging from 5 to 30 cm2, located centrally in the selected 7 x 7 cm TWA.
• exposed sub-epidermal tissue to allow absorption of the IMP.
• no suspicion of current squamous cell carcinoma (SCC) upon visual inspection.

You may not qualify if…

• Pregnant or breast-feeding female
• Hemoglobin level at Screening requiring transfusion. The subject may be rescreened when the condition is considered stable.
• Use of aminoglycosides, by any route of administration, except eye drops, 7 days or 5 half-lives, whichever is longer, prior to Baseline visit.
• Untreated carcinoma of the TWA or history of carcinoma within 5 years prior to Screening, except adequately treated cutaneous squamous or basal cell carcinoma.
• Life expectancy less than 6 months, as assessed by the Investigator
• Current or known history of clinically significant hepatic or renal disease, that in the opinion of the Investigator, could impact subject safety or study participation.
• Treatment with any systemic immunomodulators, immunosuppressants or cytotoxic chemotherapy within 2 months prior to the Baseline visit.
• Use of any investigational drug or device within 28 days or 5 half-lives of the Baseline visit, whichever is longer, or plans to participate in another study of a drug or device during the study period. The washout of 5 half-lives does not apply to gene and cell therapy.
• Known hypersensitivity to oligonucleotide treatment or excipients of the IMP.
• Bleeding disorder or condition requiring the use of anticoagulants to be confirmed by aPTT by local lab within 48 hours of first treatment.
• Use of systemic or topical steroids within 1 month prior to the baseline visit (inhaled and ophthalmic drops of corticosteroids or low dose topical solution of budesonide for esophagial strictures may be allowed).

Where it is running

• Stanford University School of Medicine, LPCH — Palo Alto, California, United States
• Children's Hospital Colorado — Aurora, Colorado, United States
• Journey Clinic, Center for Pediatric Blood and Marrow Transplantation — Minneapolis, Minnesota, United States
• Cincinnati Children's Hospital — Cincinnati, Ohio, United States
• Hopital Necker Enfants Malades — Paris, France
• Hospital Universitario La Paz — Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.